Intellia Therapeutics Inc Cash Flow Conversion Efficiency
Intellia Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) has a cash flow conversion efficiency ratio of -0.103x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.28 Million) by net assets ($671.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Intellia Therapeutics Inc (2014–2025)
Cash flow conversion efficiency of Intellia Therapeutics Inc from 2014 to 2025. This chart illustrates how Intellia Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Intellia Therapeutics Inc stock price for real-time trading data and today's change.
Intellia Therapeutics Inc Cash Flow Conversion Ratio Explained
Intellia Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Intellia Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intellia Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Intellia Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kardigan, Inc. Common Stock
NASDAQ:KARD
|
-0.082x |
|
Maharashtra Scooters Limited
NSE:MAHSCOOTER
|
0.007x |
|
PROG Holdings Inc
NYSE:PRG
|
0.222x |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
0.004x |
|
MicroPort Scientific Corporation
F:MSK
|
-0.055x |
|
Telecom Argentina SA ADR
NYSE:TEO
|
0.106x |
|
Cardinal Energy Ltd
TO:CJ
|
0.119x |
|
Shanghai Milkground Food Tech Co Ltd
SHG:600882
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Intellia Therapeutics Inc from 2014 to 2025. Review NTLA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $671.39 Million | $-348.88 Million | -0.520x | -29.87% |
| 2024-12-31 | $871.96 Million | $-348.88 Million | -0.400x | -6.62% |
| 2023-12-31 | $1.05 Billion | $-394.09 Million | -0.375x | -39.12% |
| 2022-12-31 | $1.24 Billion | $-333.29 Million | -0.270x | -24.69% |
| 2021-12-31 | $1.04 Billion | $-225.03 Million | -0.216x | -128.44% |
| 2020-12-31 | $527.07 Million | $-49.91 Million | -0.095x | +75.25% |
| 2019-12-31 | $269.88 Million | $-103.24 Million | -0.383x | -73.56% |
| 2018-12-31 | $277.92 Million | $-61.26 Million | -0.220x | -1.50% |
| 2017-12-31 | $300.60 Million | $-65.28 Million | -0.217x | -226.19% |
| 2016-12-31 | $209.84 Million | $36.11 Million | 0.172x | +757.44% |
| 2015-12-31 | $67.36 Million | $-1.76 Million | -0.026x | +94.31% |
| 2014-12-31 | $7.57 Million | $-3.48 Million | -0.460x | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more